Galectin Therapeutics (GALT) Profit After Tax (2010 - 2026)
Galectin Therapeutics' quarterly Profit After Tax came in at -$5.0 million in Q1 2026, up 47.61% year-on-year from -$3.4 million in Q1 2025, and up 8.25% quarter-over-quarter from -$5.5 million in Q4 2025.
Galectin Therapeutics has reported Profit After Tax for 17 years, with the latest figure at -$5.0 million in Q1 2026.
- For the quarter ending Q1 2026, Profit After Tax rose 47.61% year-over-year to -$5.0 million; the trailing twelve-month figure through Mar 2026 stood at -$26.3 million (up 41.91% YoY), and the FY2025 full-year result was -$30.8 million, up 34.46% from the prior year.
- Profit After Tax for Q1 2026 stood at -$5.0 million, up from -$5.5 million in the prior quarter.
- The five-year high for Profit After Tax was -$5.0 million in Q1 2026, with the low at -$12.4 million in Q2 2024.
- Average Profit After Tax over 5 years is -$9.6 million, with a median of -$9.9 million recorded in 2022.
- Year-over-year, Profit After Tax slumped 56.71% in 2022 and jumped 54.04% in 2025.
- Tracing GALT's Profit After Tax over 5 years: stood at -$10.6 million in 2022, then grew by 5.99% to -$10.0 million in 2023, then retreated by 19.71% to -$12.0 million in 2024, then jumped by 54.04% to -$5.5 million in 2025, then increased by 8.25% to -$5.0 million in 2026.
- The last three Profit After Tax figures came in at -$5.0 million (Q1 2026), -$5.5 million (Q4 2025), and -$8.2 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -2.99 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 30.90 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | -3.63 Mn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 727.20 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Galectin Therapeutics | 165.77 Mn | 151.67 Mn | - | -5.05 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -5.05 Mn |
| Dec 31, 2025 | -5.50 Mn |
| Sep 30, 2025 | -8.18 Mn |
| Jun 30, 2025 | -7.52 Mn |
| Mar 31, 2025 | -9.63 Mn |
| Dec 31, 2024 | -11.97 Mn |
| Sep 30, 2024 | -11.22 Mn |
| Jun 30, 2024 | -12.37 Mn |
| Mar 31, 2024 | -11.49 Mn |
| Dec 31, 2023 | -10.00 Mn |
| Sep 30, 2023 | -10.43 Mn |
| Jun 30, 2023 | -9.11 Mn |
| Mar 31, 2023 | -11.53 Mn |
| Dec 31, 2022 | -10.63 Mn |
| Sep 30, 2022 | -8.60 Mn |
| Jun 30, 2022 | -9.61 Mn |
| Mar 31, 2022 | -9.93 Mn |
| Dec 31, 2021 | -7.22 Mn |
| Sep 30, 2021 | -8.52 Mn |
| Jun 30, 2021 | -8.45 Mn |
| Mar 31, 2021 | -6.34 Mn |
| Dec 31, 2020 | -7.85 Mn |
| Sep 30, 2020 | -5.94 Mn |
| Jun 30, 2020 | -6.11 Mn |
| Mar 31, 2020 | -3.56 Mn |
| Dec 31, 2019 | -5.14 Mn |
| Sep 30, 2019 | -2.78 Mn |
| Jun 30, 2019 | -3.00 Mn |
| Mar 31, 2019 | -2.38 Mn |
| Dec 31, 2018 | -3.05 Mn |
| Sep 30, 2018 | -2.75 Mn |
| Jun 30, 2018 | -3.84 Mn |
| Mar 31, 2018 | -4.26 Mn |
| Dec 31, 2017 | -2.38 Mn |
| Sep 30, 2017 | -4.41 Mn |
| Jun 30, 2017 | -4.51 Mn |
| Mar 31, 2017 | -4.94 Mn |
| Dec 31, 2016 | -4.59 Mn |
| Sep 30, 2016 | -4.53 Mn |
| Jun 30, 2016 | -5.52 Mn |
| Mar 31, 2016 | -6.80 Mn |
| Dec 31, 2015 | -4.67 Mn |
| Sep 30, 2015 | -5.89 Mn |
| Jun 30, 2015 | -4.64 Mn |
| Mar 31, 2015 | -4.83 Mn |
| Dec 31, 2014 | -3.73 Mn |
| Sep 30, 2014 | -3.52 Mn |
| Jun 30, 2014 | -3.43 Mn |
| Mar 31, 2014 | -5.11 Mn |
| Dec 31, 2013 | -2.80 Mn |
| Sep 30, 2013 | -3.54 Mn |
| Jun 30, 2013 | -2.54 Mn |
| Mar 31, 2013 | -3.20 Mn |
| Dec 31, 2012 | -2.38 Mn |
| Sep 30, 2012 | -2.69 Mn |
| Jun 30, 2012 | -2.66 Mn |
| Mar 31, 2012 | -1.95 Mn |
| Dec 31, 2011 | -3.37 Mn |
| Sep 30, 2011 | -2.03 Mn |
| Jun 30, 2011 | -3.13 Mn |
| Mar 31, 2011 | -2.39 Mn |
| Dec 31, 2010 | -728,000.00 |
| Sep 30, 2010 | -1.11 Mn |
| Jun 30, 2010 | -1.65 Mn |